The key catalyst is the November 30 PDUFA date for bezuclastinib in GIST; approval would trigger a commercial launch and potential revenue inflection. Monitor the ASH 2026 presentations (Dec 12-15) for SUMMIT trial data on symptom burden and the avapritinib-to-bezuclastinib switch sub-study.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 6 $31.65entry
- T+1 · 8d ago +5.99%α +3.62% · $33.54
- T+5 · 4d ago −9.75%α −12.34% · $28.56
- T+6 · todayOpen
- T+20 · in 20d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Cogent Biosciences reported Q3 2026 net loss of $111.4M, wider than the $80.9M loss in Q3 2025, driven by increased R&D and G&A spending ahead of the anticipated bezuclastinib launch. The company maintains a strong cash position of $791.1M, sufficient into late 2028, and is approaching three PDUFA dates starting November 30, 2026 for GIST.
Key Financial Metrics
Key Facts
- Net loss of $111.4M in Q3 2026 vs $80.9M in Q3 2025
- Cash, cash equivalents and marketable securities of $791.1M as of September 30, 2026
- PDUFA target action date for bezuclastinib in GIST is November 30, 2026
- PDUFA target action date for bezuclastinib in NonAdvSM is December 30, 2026
- PDUFA target action date for bezuclastinib in AdvSM is June 29, 2027
- R&D expenses were $75.1M in Q3 2026 vs $69.0M in Q3 2025
- G&A expenses were $42.1M in Q3 2026 vs $14.4M in Q3 2025
- IND applications for CGT1815 (pan-KRAS inhibitor) and CGT1145 (JAK2 V617F inhibitor) expected in Q4 2026
Financial Impact
Net loss of $111.4M in Q3 2026, cash burn of ~$1.2M from prior quarter; cash runway into late 2028
Risk Factors
- FDA non-approval or delayed action on any of the three bezuclastinib NDAs
- Higher-than-expected cash burn from commercial readiness spending
- Clinical trial execution risk for the PEAK extension cohort and pipeline IND filings
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3396995 |
Track record
13 reports on COGT
5 of 6 bullish or bearish reports moved the stock their way by T+60. Best: +17.43% at T+20 after the Jun 12, 2026 report. 5 of 6 went positive at some point.
Filters
- Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $33.54 Now $27.44 −18.19% settles Feb 5
- Nov 5, 202611d ago 8-K Neutral 4/10 No price data
- Nov 5, 202611d ago Press Release Neutral 5/10 Viewing Entry $31.65 Now $27.44 −13.29% settles Feb 4
- Aug 10, 202614w ago 8-K Neutral 5/10 No price data
- Aug 10, 202614w ago Press Release Neutral 5/10 Entry $41.53 to $31.06 Now $27.44 −33.93% ▼ −25.21% −22.79% vs SPY
- Aug 9, 202614w ago Institutional Cluster Bullish 6/10 Entry $41.53 to $31.06 Now $27.44 −33.93% ▼ −25.21% −22.79% vs SPY
- Jun 12, 202622w ago Press Release Neutral 4/10 Entry $33.10 to $35.28 Now $27.44 −17.10% ▲ +6.59% +3.32% vs SPY
- Jun 12, 202622w ago Press Release Bullish 7/10 Entry $33.10 to $35.28 Now $27.44 −17.10% ▲ +6.59% +3.32% vs SPY
- May 30, 202624w ago Press Release Bullish 8/10 Entry $34.81 to $36.80 Now $27.44 −21.17% ▲ +5.72% +4.49% vs SPY
- May 28, 202624w ago Press Release Bullish 8/10 Entry $35.38 to $36.73 Now $27.44 −22.44% ▲ +3.82% +2.08% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers